Recent studies have demonstrated that there is no significant difference in patient survival between the targeted-first therapy and radiotherapy-first treatment sequences in patients with EGFR mutation-positive lung cancer brain metastases 16-18. The gene discussed is EGFR; the disease is lung carcinoma.